Advanced Kidney Cancer VL

Adding Fecal Microbiota Transplantation (FMT) in Combination with Immunotherapy to Treat Renal Cell Carcinoma, The PERFORM Study - Ricardo Fernandes

Details
Ricardo Fernandes joins Pedro Barata in a discussion on PERFORM, an ongoing phase I study evaluating the safety of fecal microbiota transplantation (FMT) and immunotherapy combination in first-line (1L) metastatic renal cell carcinoma, and assessing whether FMT will prevent or mitigate immune-related adverse events. Dr. Fernandes details what led to the design and conduct of PERFORM. The study aim...

OMNIVORE - Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma, Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss the OMNIVORE study published in the Journal of Clinical Oncology. This phase II response-adaptive trial investigated the rational application of immune checkpoint blockade in renal cell carcinoma. Biographies: Christopher J.D. Wallis, MD, Ph.D., Assistant Professor in the Division of Urology at the University of Toronto. Zachary Klaassen, MD, MSc, Ur...

Final Results of TITAN-RCC Trial - Is a Tailored Approach of Nivolumab and Nivolumab/Ipilimumab as Immunotherapeutic Boost Recommended - Marc-Oliver Grimm

Details
Marc-Oliver Grimm joins Pedro Barata in a discussion on the final results of the TITAN-RCC trial, assessing a tailored approach to systemic therapy in patients with metastatic renal cell carcinoma (mRCC). The TITAN-RCC was designed many years ago, when nivolumab + ipilimumab (NIVO/IPI) was not approved yet as a first-line treatment. During this time the pivotal CheckMate 214 trial was still in pro...

Is There Still a Role for Cytoreductive Nephrectomy? Analysis from the CARMENA Trial, Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss an update on the CARMENA trial. CARMENA was a phase III trial in 450 patients with metastatic renal cell carcinoma (mRCC) enrolled from 2009 to 2017. The objective of this study was to provide updated overall survival (OS) outcomes of CARMENA and assess whether some subgroups may still benefit from upfront cytoreductive nephrectomy. Biographies: Chri...

The First Neoadjuvant Trial Using Combination Immune Checkpoint Inhibitor and VEGF Inhibitor in Patients With Locally Advanced High-Risk RCC (NeoAvAx) – Axel Bex

Details
Axel Bex joins Alicia Morgans to discuss the results of the NeoAvAx trial examining neoadjuvant avelumab and axitinib following nephrectomy for patients who are at high risk for recurrence. The NeoAvAx trial tests the neoadjuvant use of a combination of the immune checkpoint inhibitor avelumab and the VEGF-inhibitor axitinib. Biographies: Axel Bex, MD, PhD, Urologic Surgeon, Royal Free London NHS...

The Upcoming 2022 European International Kidney Cancer Symposium - Samra Turajlic

Details
Medical Oncologist and member of the scientific committee of the upcoming European International Kidney Cancer Symposium, Samra Turajlic joins Rana McKay to discuss the upcoming IKCS meeting being held April 22nd through the 24th in Antwerpen, Belgium. The program will consist of Award Lectures in Urology and Oncology, Basic Science in renal cell carcinoma (RCC), Biomarkers in RCC, Diagnostics, an...

KEYNOTE-564 30-Month Follow-Up of Pembrolizumab as Post Nephrectomy Adjuvant Therapy for Patients with Renal Cell Carcinoma - Toni Choueiri

Details
Alicia Morgans is joined by Toni Choueiri to discuss his GU ASCO 2022 presentation on a 30-month follow-up from the KEYNOTE-564 trial of post-nephrectomy adjuvant pembrolizumab in patients with renal cell carcinoma (RCC). Dr. Choueiri highlights that adjuvant pembrolizumab continued to demonstrate a disease-free survival (DFS) benefit following nephrectomy for patients with intermediate-high or hi...

42-Month Follow-up of KEYNOTE-426, Pembrolizumab plus Axitinib First-Line Treatment for Advanced Renal Cell Carcinoma - Thomas Powles

Details
Alicia Morgans, MD, MPH, and Thomas Powles, MBBS, MRCP, MD, discuss the recent ASCO presentation on 42 -month follow-up from the KEYNOTE-426 study. The KEYNOTE-426 study is a randomized phase three study looking at combination therapies of axitinib and pembrolizumab versus sunitinib, in metastatic kidney cancer. Biographies: Thomas Powles, MBBS, MRCP, MD, Professor of Genitourinary Oncology, Lead...

Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma, The CLEAR Trial Journal Club - Christopher Wallis & Zachary Klaassen

Details
At the 2021 ASCO GU Cancers Symposium, Dr Robert Motzer and colleagues presented the results of the CLEAR study examining first-line lenvatinib and everolimus or lenvatinib and pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma and concurrent with the presentation, CLEAR was published in the New England Journal of Medicine. In this UroToday Journal Club, Christopher Wall...

VEGF Blockade and Combination Therapeutic Options in Advanced Renal Cell Carcinoma - Andrea Apolo

Details
In this conversation, Rana McKay and Andrea Apolo highlight several studies presented during the ASCO 2021 Annual Meeting on combination therapeutic options for advanced renal cell carcinoma (RCC). Dr. Apolo expands on several studies she highlighted in her presentation and where these treatment options fit into the treatment landscape of advanced RCC potentially enhancing the immune effect of imm...
email news signup